NobelDirect – Analysts` Report on Bone Loss Controversy

Merrill Lynch and UBS have released stock research reports regarding Nobel Biocare`s NobelDirect implant design. Several recent studies suggest more than 3mm of bone loss in 14-55% of patients. An expert panel advising the Swedish Medical Products Agency on the safety of the NobelDirect implant has responded to a recent Nobel Biocare rebuttal letter in a critical manner. The Merrill Lynch analyst suggests a NobelDirect withdrawal may be ahead.

Leave a Reply

Your email address will not be published.